Nuformix plc (LON:NFX – Get Free Report)’s share price was down 10% on Monday . The stock traded as low as GBX 0.05 ($0.00) and last traded at GBX 0.05 ($0.00). Approximately 1,986,748 shares were ...
Adjuvant olaparib continued to show a strong efficacy benefit in patients with BRCA1/2 mutation–positive, HER2-negative ...
About 87.5% of patients treated with the drug were alive after six years, compared to 83.2% who received a placebo.
The following is a summary of “Olaparib as Treatment Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive ...
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
At six years, 79.6% of olaparib-treated patients remained free of invasive recurrence and 83.5% remained free of distant recurrence, compared to 70.3% and 75.7%, respectively, in the placebo group.
These data reinforce the importance of germline BRCA testing at the time of diagnosis, so we can identify all eligible patients who may benefit from treatment with olaparib as early as possible." ...
--(BUSINESS WIRE)--Updated results from the OlympiA Phase III trial showed AstraZeneca and Merck & Co., Inc’s, known as MSD outside of the US and Canada, LYNPARZA ® (olaparib) demonstrated ...